SERB Pharma to acquire Y-mAbs Therapeutics for $412m
The acquisition will enhance SERB's portfolio in rare diseases and medical emergencies, strengthening its position in the global pharmaceutical market.
Analysis
View MoreThe ultimate hub for fine and speciality chemicals
Chemspec Europe 2025 returns to Cologne with expanded exhibition space, enhanced digital tools, and a diverse line-up of industry leaders. This premier event will showcase cutting-edge solutions across key sectors,...
Seal the deal
Excipient evolution shaping pharma innovation
Solving the EDDO guidance puzzle
AI-driven delivery